Intellia Therapeutics (NTLA) Other Gross PP&E Adjustments (2016 - 2025)
Historic Other Gross PP&E Adjustments for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$120.6 million.
- Intellia Therapeutics' Other Gross PP&E Adjustments fell 1708.51% to -$120.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.6 million, marking a year-over-year decrease of 1708.51%. This contributed to the annual value of -$145.1 million for FY2024, which is 9827.92% down from last year.
- Latest data reveals that Intellia Therapeutics reported Other Gross PP&E Adjustments of -$120.6 million as of Q3 2025, which was down 1708.51% from -$131.8 million recorded in Q2 2025.
- Intellia Therapeutics' Other Gross PP&E Adjustments' 5-year high stood at -$5.5 million during Q2 2021, with a 5-year trough of -$145.1 million in Q4 2024.
- Moreover, its 5-year median value for Other Gross PP&E Adjustments was -$104.3 million (2022), whereas its average is -$93.0 million.
- As far as peak fluctuations go, Intellia Therapeutics' Other Gross PP&E Adjustments soared by 7827.77% in 2021, and later plummeted by 129748.02% in 2022.
- Intellia Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at -$39.8 million in 2021, then tumbled by 137.15% to -$94.5 million in 2022, then grew by 22.55% to -$73.2 million in 2023, then crashed by 98.28% to -$145.1 million in 2024, then grew by 16.86% to -$120.6 million in 2025.
- Its Other Gross PP&E Adjustments stands at -$120.6 million for Q3 2025, versus -$131.8 million for Q2 2025 and -$141.2 million for Q1 2025.